Novitium Pharma LLC | ANI Pharmaceuticals Inc.

The U.S. Federal Trade Commission filed a complaint against a transfer of assets from Novitium Pharma LLC to ANI Pharmaceuticals Inc. in the markets for (i) the development, license, manufacture, marketing, distribution, and sale of sulfamethoxazole-trimethoprim (“SMX-TMP”) oral suspension and (ii) the development, license, manufacture, marketing, distribution, and sale of dexamethasone tablets.